![](/img/cover-not-exists.png)
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
Yoh, Kiyotaka, Doi, Toshihiko, Ohmatsu, Hironobu, Kojima, Takashi, Takahashi, Hideaki, Zenke, Yoshitaka, Wacheck, Volker, Enatsu, Sotaro, Nakamura, Takashi, Turner, Kellie, Uenaka, KazunoriVolume:
34
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-016-0370-7
Date:
October, 2016
File:
PDF, 952 KB
english, 2016